openPR Logo
Press release

Gram-Positive Bacterial Infections Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

04-04-2019 01:54 PM CET | Health & Medicine

Press release from: Pharma Proff

Gram-Positive Bacterial Infections Therapeutics- Pipeline

Gram-positive bacterial infections are caused by gram-positive bacteria, such as Staphylococcus aureus and Enterococcus spp. This infection sometimes become fatal in the immune-compromised person, and it is generally found in new-born.

Download the sample report @ https://www.pharmaproff.com/request-sample/1060

The infection when contracted during pregnancy can cause chorioamnionitis and postpartum infections. Further, urinary tract infections associated with the bacteria can also cause premature birth.

Get the detailed analysis @ https://www.pharmaproff.com/report/gram-positive-bacterial-infections-therapeutics-pipeline-analysis

Some of the characteristics of gram-positive bacteria are thick peptidoglycan layer, presence of teichoic acids, DD-transpeptidase for cross-linking in the cell walls, and cytoplasmic lipid membrane. Gram-positive bacteria give positive result in gram stain test.

Make enquiry before purchase @ https://www.pharmaproff.com/enquiry/1060

Merck & Co. Inc. is in the process of developing tedizolid phosphate for the treatment of gram-positive bacterial infections. Pfizer Inc. is also involved in the pipeline for Gram-positive bacterial infections.
• The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
• Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.

Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gram-Positive Bacterial Infections Therapeutics- Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments here

News-ID: 1688278 • Views: 336

More Releases from Pharma Proff

Interleukin-6 (IL-6) Inhibitors Analysis, Clinical Trails and Developments
Interleukin-6 (IL-6) inhibitors currently exhibit a proliferating pipeline with 25+ therapeutic candidates. IL-6 is a cytokine encoded by IL-6 gene, which helps in the maturation of B cells and is actively involved in the inflammatory response. The IL-6 protein is primarily produced at the sites of acute and chronic inflammation, where it is secreted into the serum and brings a transcriptional inflammatory response through IL-6? receptor. This protein is assumed to
Retinitis Pigmentosa Therapeutics Analysis, Clinical Trials and Other Developmen …
Retinitis pigmentosa therapeutics currently exhibits a proliferating pipeline with 25+ therapeutic candidates. Retinitis pigmentosa (RP) is a group of hereditary disorders that lead to the breakdown and loss of cells in the retina. Mutation in genes encoding the proteins required by retinal cells for their proper functioning, results in occurrence of RP. The disease results in partial vision loss during the earlier stage of the disease, which may lead to complete
Probiotics Therapeutics -Pipeline Analysis 2018, Clinical Trials & Results, Pate …
Probiotics are live microorganisms that produces beneficial effects in human gut. Probiotics can be taken as a dietary supplement. They prevent diarrhoea and help to reduce the symptoms of irritable bowel syndrome. Download the sample report at: https://www.pharmaproff.com/request-sample/1189 Probiotics comprise of a variety of microorganisms belonging to the Lactobacillus and Bifidobacterium groups. The only yeast probiotic that has proven to be effective is Saccharomyces boulardii. According to researchers, probiotics are effective in
Niemann-Pick Disease Type C (NPC) Therapeutics Pipeline to Witness Significant G …
Niemann-Pick disease is divided into four main types: type A, type B, type C1, and type C2. These types are classified on the basis of genetic cause and signs and symptoms of the disease. NPC is identified as a rare genetic disorder in which the body is unable to transport cholesterol and lipids inside the cells. This causes accumulation of these substances within various tissues of the body. These substances

All 5 Releases


More Releases for Pipeline

Gastroenteritis Therapeutics Pipeline Analysis 2018
Gastroenteritis, also known as infectious diarrhoea, is an inflammatory disease caused by bacteria, viruses, or parasites through contaminated food and water. Download the sample report at: https://www.pharmaproff.com/request-sample/1028 The disease can be symptomatized by vomiting, nausea, cramping, and diarrhoea. Dehydration, joint inflammation, conjunctivitis, salmonella infection, persistent diarrhoea syndrome, lactose intolerance, and irritable bowel syndrome are among the several complications associated with gastroenteritis. Get the detailed analysis at: https://www.pharmaproff.com/report/gastroenteritis-therapeutics-pipeline-analysis The treatment medications for the disease
Hyperalgesia Therapeutics- Pipeline Analysis 2018
Hyperalgesia is a medical condition in which a person develops an increased sensitivity towards pain. There are several nerve pathways in the body where signals can start miscommunication with each other, resulting in hyperalgesia. Download the sample report @ https://www.pharmaproff.com/request-sample/1100 Hyperalgesia can be categorized into several types which includes primary, secondary and opioid-induced hyperalgesia. The main symptom associated with the disease is increasing extreme reaction to painful stimuli without any new injury.
Autism-Pipeline Review H1 2018
ReportsWeb.com has announced the addition of the “Global Autism Market Size Status and Forecast 2018”, The report classifies the global Autism Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. Pharmaceutical and Healthcare disease pipeline guide Autism-Pipeline Review, H1 2018, provides an overview of the Autism (Central Nervous System) pipeline landscape.Autism, also known as complex
Osteoarthritis-Pipeline Review H2 2017
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis-Pipeline Review, H2 2017, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape. Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint
Hypotension (Cardiovascular) Pipeline Review H2, 2017 - Pharmaceutical Pipeline …
Market Research Hub's latest Pharmaceutical and Healthcare disease pipeline guide Hypotension Pipeline Review, H2 2017, provides an overview of the Hypotension (Cardiovascular) pipeline landscape. Low blood pressure, or hypotension, occurs when blood pressure during and after each heartbeat is much lower than usual. This means the heart, brain, and other parts of the body do not get enough blood. Symptoms include blurred vision, dizziness, confusion, sleeplessness and weakness. Treatment is
Insomnia (Central Nervous System) pipeline landscape - Pipeline Review, H1 2017
Latest Pharmaceutical and Healthcare disease pipeline guide “Insomnia Pipeline Review H1” 2017, provides an overview of the Insomnia (Central Nervous System) pipeline landscape. Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches and distress in the stomach and intestines. Risk factors include age, mental health disorder, stress and shift working. Report Highlights Global Markets Direct's